SRP0702

SORAFENIB

recombinant

• UNSPSC-Code: 12352202
• NACRES: NA.77

Eigenschaften

• Assay: >95% (TLC)
• Form: lyophilized powder
• Mol-Gew.: ~464.8
• Versandbedingung: ambient
• Lagertemp.: −20°C

Beschreibung

Anwendung

Clinically useful anticancer agent.

Biochem./physiol. Wirkung

Initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-beta (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM) ⁽¹⁾. Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms ⁽²⁾. Inhibits activation of MAPK pathway and ERK phosphorylation ⁽³⁾. Induces caspase-independent apoptosis in melanoma cells ⁽⁴⁾.

Rekonstituierung

Formulated as a lyophilized powder. May be dissolved in DMSO (200 mg/mL) or Ethanol (3 mg/mL).

Lagerung und Haltbarkeit

Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month.

Sicherheitshinweise

• Piktogramme: GHS08,GHS09
• Signalwort: Danger
• H-Sätze: H360FD,H362,H372,H410
• P-Sätze: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Gefahreneinstufungen: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• Lagerklassenschlüssel: 6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable